A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
10 Mar 2023
10 Mar 2023
Historique:
received:
11
10
2022
accepted:
09
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
10
3
2023
Statut:
epublish
Résumé
Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.
Identifiants
pubmed: 36894570
doi: 10.1038/s41541-023-00624-y
pii: 10.1038/s41541-023-00624-y
pmc: PMC9998260
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Subventions
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1195433
Informations de copyright
© 2023. The Author(s).
Références
J Immunol. 2003 Nov 15;171(10):4969-73
pubmed: 14607890
J Infect Dis. 1998 Apr;177(4):1112-5
pubmed: 9534995
Clin Infect Dis. 2016 Mar 15;62(6):722-729
pubmed: 26679624
Vaccines (Basel). 2022 Apr 01;10(4):
pubmed: 35455297
Vaccine. 2016 Jun 3;34(26):2865-2869
pubmed: 26993336
Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):123-6
pubmed: 11305466
ACS Cent Sci. 2022 Apr 27;8(4):449-460
pubmed: 35559427
J Immunol Methods. 2013 May 31;391(1-2):50-9
pubmed: 23454005
Clin Microbiol Infect. 2023 Mar;29(3):366-371
pubmed: 36243351
Lancet Glob Health. 2018 Dec;6(12):e1319-e1328
pubmed: 30287125
Front Immunol. 2019 Jul 31;10:1787
pubmed: 31417562
Front Immunol. 2021 May 04;12:671325
pubmed: 34017343
BMC Infect Dis. 2016 Nov 18;16(1):685
pubmed: 27863468
J Infect Dis. 2022 May 4;225(9):1500-1503
pubmed: 34558631
J Immunol. 2009 Feb 15;182(4):2241-7
pubmed: 19201878
Vaccines (Basel). 2022 Jan 29;10(2):
pubmed: 35214671
J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S829-S839
pubmed: 34374425
Clin Infect Dis. 1992 Aug;15(2):346-61
pubmed: 1381621
Vaccines (Basel). 2022 Feb 18;10(2):
pubmed: 35214786
Glycobiology. 2011 Dec;21(12):1570-9
pubmed: 21610193
J Immunol. 2014 Apr 1;192(7):3091-100
pubmed: 24567530
Emerg Infect Dis. 2008 Aug;14(8):1297-9
pubmed: 18680661
Nat Rev Microbiol. 2007 Jul;5(7):540-53
pubmed: 17558427
Clin Infect Dis. 2014 Oct;59(7):933-41
pubmed: 24958238
J Infect Dis. 2001 Nov 1;184(9):1211-5
pubmed: 11598848
PLoS One. 2021 May 27;16(5):e0252222
pubmed: 34043697
PLoS Negl Trop Dis. 2020 Aug 17;14(8):e0008536
pubmed: 32804926
EBioMedicine. 2017 Aug;22:164-172
pubmed: 28735965
Vaccine. 2009 Jun 24;27 Suppl 2:B112-6
pubmed: 19464093
Vaccine. 2016 Jun 8;34(27):3132-3140
pubmed: 27133878
Pediatr Infect Dis J. 2003 Aug;22(8):701-6
pubmed: 12913770
Lancet Infect Dis. 2021 Apr;21(4):546-558
pubmed: 33186516
Vaccines (Basel). 2022 Apr 24;10(5):
pubmed: 35632431
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
EClinicalMedicine. 2021 Aug 13;39:101076
pubmed: 34430837
Methods Mol Med. 2001;66:289-304
pubmed: 21336762
Clin Vaccine Immunol. 2017 Feb 6;24(2):
pubmed: 27927680
Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917
pubmed: 27581434
Lancet Glob Health. 2018 Mar;6(3):e255-e269
pubmed: 29433665
Vaccine. 2002 Jun 7;20(19-20):2592-6
pubmed: 12057617
Mil Med. 2017 Sep;182(S2):4-10
pubmed: 28885918
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9976-81
pubmed: 18621718
Vaccine. 2010 Mar 2;28(10):2231-2235
pubmed: 20056180
Vaccines (Basel). 2022 Aug 24;10(9):
pubmed: 36146457
J Infect Dis. 1989 Jun;159(6):1126-8
pubmed: 2656880
EBioMedicine. 2021 Apr;66:103310
pubmed: 33862589
Sex Transm Infect. 2015 Dec;91(8):598-602
pubmed: 25921020
JAMA. 2016 Jun 28;315(24):2712-23
pubmed: 27357241
Vaccine. 2001 Nov 12;20(3-4):498-504
pubmed: 11672915
Vaccines (Basel). 2022 Mar 07;10(3):
pubmed: 35335035
Am J Epidemiol. 1991 Sep 15;134(6):614-27
pubmed: 1951266
Lancet. 1997 Jan 18;349(9046):155-9
pubmed: 9111538
J Immunol Methods. 2013 Aug 30;394(1-2):84-93
pubmed: 23707324
Infect Immun. 1996 Oct;64(10):4074-7
pubmed: 8926071
Epidemiol Infect. 2014 Dec;142(12):2583-94
pubmed: 24559503
Vaccine. 1999 Aug 6;17(23-24):3109-15
pubmed: 10462247
EBioMedicine. 2021 Apr;66:103308
pubmed: 33813141
Bioconjug Chem. 2016 Apr 20;27(4):883-92
pubmed: 26918643
Infect Immun. 2001 Mar;69(3):1351-7
pubmed: 11179298
J Clin Microbiol. 1989 Jan;27(1):162-7
pubmed: 2463995
Lancet Infect Dis. 2018 Nov;18(11):1229-1240
pubmed: 30266330
Hum Vaccin Immunother. 2019;15(6):1401-1408
pubmed: 31070988
Chemistry. 2005 Feb 18;11(5):1625-35
pubmed: 15669066